Figure 4 : Common marker pathway (CMP) index for responders/non-responders to paclitaxel treatment of ERN HER2P and ERN HER2N breast cancer types.

From: In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development

Figure 4

The index is calculated for four independent data sets obtained from GEO (GSE20194, GSE20271, GSE32646 and GSE50948) for each cancer type. Index demonstrates the robustness of the pathway marker lists between data sets. Independent application of the gene modules and topological coefficients did not improve the robustness of the algorithm for estimation of pathway activation; however, combined application resulted in significant improvement.